Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca - LARVOL DELTA

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: University of California, San Francisco

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Biologic Treatments in Adolescents With Moderate-to-Severe Atopic Dermatitis: A Systematic Literature Review and Network Meta-analysis. (PubMed, Ann Pharmacother) - "Although there is some evidence that dupilumab may be more efficacious than lebrikizumab or tralokinumab, our findings suggest that there is no strong evidence of superiority of one treatment over another."

Clinical • Journal • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

LEO Pharma Presents Twenty-Three Posters at Maui Derm Hawaii 2026, Demonstrating Continued Commitment to Scientific Innovation in Medical Dermatology (Yahoo Finance) - "The posters comprise clinical, real‑world and U.S.-focused analyses, including patient-reported outcomes, long-term results, and health economic assessments for ADBRY (tralokinumab‑ldrm) and ANZUPGO (delgocitinib) cream, as well as a post‑marketing study evaluating the efficacy of SPEVIGO (spesolimab-sbzo). These data follow the presentation of 22 posters at Winter Clinical Hawaii."

Clinical data • Atopic Dermatitis • Dermatology • Pustular Psoriasis

Novel Therapeutic Strategies for Atopic Dermatitis: Biomarker Modulation and Clinical Implications. A Systematic Review. (PubMed, Clin Rev Allergy Immunol) - "Dupilumab was the most extensively investigated therapy, followed by tralokinumab, JAK inhibitors, and novel agents such as amlitelimab, stapokibart, and tezepelumab...CCL17 and LDH currently represent the most reliable biomarkers associated with disease severity and treatment response, although their limited specificity restricts clinical applicability. Future research should aim to validate integrated biomarker panels combining immunologic, transcriptomic, and microbiomic data to enable precision medicine approaches in atopic dermatitis management."

Biomarker • Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND. (PubMed, Dermatol Ther (Heidelb)) - P3 | "Long-term tralokinumab treatment for up to 6 years (parent trials plus ECZTEND) in patients ≥ 12 years with moderate-to-severe AD was well tolerated and maintained long-term efficacy. A graphical abstract is available for this article."

Journal • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Pain • Respiratory Diseases

Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International Cohort. (PubMed, Dermatol Ther (Heidelb)) - "Nearly one-quarter of real-world patients with AD would not have met eligibility criteria for pivotal RCTs, yet both biologics and JAK inhibitors demonstrated acceptable safety profiles in these populations. While adverse events were more frequent among ineligible patients receiving JAKis, findings require further investigation to determine their clinical relevance, particularly regarding long-term cardiovascular outcomes."

Clinical • Journal • Real-world evidence • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Immunology

U090 - Practical Considerations for Systemic Treatment of Atopic Dermatitis in Adults (AAD 2026) - "Conventional immunomodulators (methotrexate, cyclosporine), biologics (dupilumab, tralokinumab, lebrikizumab, nemolizumab), and JAK inhibitors (abrocitinib, upadacitinib) are available, with more on the way. Recognize adverse events associated with systemic treatments for atopic dermatitis and how to monitor for and manage them. Differentiate the advantages and disadvantages of available systemic treatment options for atopic dermatitis in special populations of adults, including older adults and adults with comorbidities."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Rapid and long-lasting remission of refractory Hailey-Hailey disease by IL-13 inhibition with tralokinumab. (PubMed, J Dtsch Dermatol Ges) - No abstract available

Journal • Genetic Disorders • IL13

Real-world effectiveness and safety of tralokinumab therapy in moderate-to-severe atopic dermatitis: insights from the TREATgermany registry. (PubMed, Clin Exp Dermatol) - No abstract available

Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Long-Term, Site-Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72-Week Real-World Study. (PubMed, J Dermatol) - "Tralokinumab reduced EASI scores through 72 weeks across different anatomical sites in AD patients. The achievement rates of EASI 75 and 100 appeared slightly higher on lower limbs compared to the other sites."

Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13

Identifying Patient Sentiment in Atopic Dermatitis Treatment: Large Language Model Approach. (PubMed, JMIR Form Res) - "This study demonstrates that GPT-4o outperforms traditional natural language processing methods in accurately analyzing patient sentiment toward atopic dermatitis treatments on Reddit, enabling more nuanced and reliable extraction of real-world patient perspectives from large-scale social media data."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Biologics and Small-Molecule Inhibitors in Nummular Dermatitis: A Systematic Review. (PubMed, J Cutan Med Surg) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review. (PubMed, Ann Pharmacother) - "Lebrikizumab is an effective and well-tolerated biologic with rapid onset of action and favorable safety for treatment of moderate-to-severe AD."

Journal • Review • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • IL13 • IL4

Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies. (PubMed, Antibodies (Basel)) - "Objective: To review the efficacy and safety of current systemic treatments for HND, with a focus on dupilumab, tralokinumab, lebrikizumab, and janus kinase (JAK) inhibitors...JAK inhibitors, particularly upadacitinib, provide rapid and marked improvement in refractory cases and in patients developing FR during biologic therapy. Systemic therapy for HND should be individualized, balancing efficacy and tolerability. JAK inhibitors represent a valuable alternative in biologic-refractory phenotypes or in patients experiencing dupilumab-associated FR."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Cost per responder analysis of lebrikizumab versus tralokinumab in moderate to severe atopic dermatitis. (PubMed, Expert Rev Pharmacoecon Outcomes Res) - "In comparison to tralokinumab, lebrikizumab had a much lower number needed to treat and cost per responder. These results, based on US pricing, indicate that lebrikizumab appears to be more cost-effective treatment option based on indirect comparisons."

HEOR • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Systematic Review of FDA Approved Biologics (Dupilumab, Nemolizumab, Tralokinumab, and Lebrikizumab) Use for Moderate-to-Severe Atopic Dermatitis in Pregnancy (ASHP 2025) - No abstract available

Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Dupilumab vs. Tralokinumab in adolescent patients at Children's Mercy clinics: a comparison of benefit and adverse effects (ASHP 2025) - No abstract available

Adverse events • Clinical

P109 Lebrikizumab for the treatment of moderate-to-severe atopic eczema: real-world experience from a tertiary centre. (PubMed, Br J Dermatol) - "Ten patients experienced ocular symptoms while on dupilumab (n = 8) or tralokinumab (n = 3). Moreover, lebrikizumab serves as a viable alternative for patients who experienced ocular complications with previous biologic therapies. Further long-term follow-up is essential in larger cohorts to fully assess the future role of lebrikizumab."

Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Dry Eye Disease • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • IL13

P088 Janus kinase inhibitor treatment in coexisting atopic dermatitis and irritable bowel disease: real-world experience and therapeutic outcomes. (PubMed, Br J Dermatol) - "Despite the apparent efficacy treating IBD in this series, only two of seven patients (29%) achieved satisfactory cutaneous response to JAKi monotherapy, contrasting with established efficacy data in isolated AD. These findings raise questions about underlying disease mechanisms in this phenotype, warranting further investigation.TableTreatment of seven patients with atopic dermatitis (AD) and irritable bowel disease (IBD) with Janus kinase inhibitors (JAKis)Age (years)Primary indicationBefore JAKi treatmentOn JAKi treatmentDisease statusAD treatmentIBD treatmentJAKi therapyOutcomes50ADEASI 54; UC controlledNoneGuselkumab (stopped)Upadacitinib 24 months (ongoing)EASI 75 achieved (5.1); UC remission22AD, CDEASI 41; CD activeMethotrexate (stopped)Infliximab (stopped)Upadacitinib 4 months (ongoing)EASI 75 achieved (7.4); CD remission29ADEASI 13; UC controlledNoneAZA, allopurinol (stopped)Upadacitinib 8 months (ongoing)EASI 10.3; added methotrexate (6 months), switched to..."

Journal • Real-world evidence • Alopecia • Atopic Dermatitis • Crohn's disease • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Herpes Zoster • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster

P093 Switching patients who developed arthritis and/or enthesitis on dupilumab to tralokinumab: a case series. (PubMed, Br J Dermatol) - "Patient 2 developed bilateral shoulder, left Achilles tendon and back pain 2 years into dupilumab, which resolved when he switched to abrocitinib. To our knowledge, this is the first retrospective case series to report tralokinumab-associated inflammatory arthritis. These cases suggest that patients who develop arthritis or enthesitis on dupilumab are likely to experience similar symptoms on tralokinumab, and a treatment class switch (specifically to a Janus kinase inhibitor) can be beneficial.TablePatient characteristics Patient 1Patient 2Patient 3SexFemaleMaleFemaleAge (years)557028Eczema Area and Severity Index Baseline (pretreatment)23.630.329.5 On tralokinumab (month)6.1 (6)29.6 (4)2.1 (4)Arthropathy pattern Small joints+++ Large joints++-Enthesitis/tenosynovitis+++Ultrasound+N/A+CRP/ESRNormalN/ARaisedConcurrent managementNSAIDsN/ANSAIDsDuration of tralokinumab (months)13724Musculoskeletal symptom progressionImprovingResolvedImprovingTherapy after..."

Journal • Atopic Dermatitis • Back Pain • Dermatitis • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology • CRP • IL13

P117 Treatment and investigation of head and neck dermatitis in patients with atopic dermatitis treated with biologic and small-molecule therapies: a systematic review. (PubMed, Br J Dermatol) - "Improved/resolved HND was not reported per patient, but in one trial, the median time to 75% improvement in HND was 57 days for dupilumab (n = 238) vs. 29 days for abrocitinib 200 mg...Adverse HND was also reported for tralokinumab (3 of 49, 6%) and baricitinib (two of three, 67%)...Itraconazole led to clinical improvement in all cases that recurred on withdrawal...Future studies should compare head and neck outcomes between different biologics and JAKis. This will help improve treatment decisions for patients where HND is of particular concern."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

BI27 Treatment of recalcitrant eczema in a patient with B-cell and natural killer cell lymphopenia of unknown cause. (PubMed, Br J Dermatol) - "He had tried superpotent topical corticosteroids and oral prednisolone, as well as emollients, none of which had improved his symptoms...Tralokinumab was trialled for 12 weeks, as this has a single therapeutic target (interleukin-13), but unfortunately there was no improvement. Following discussion with the immunologists, he was commenced on upadacitinib as this was felt to have a more targeted immunosuppressive effect above agents such as methotrexate and dupilumab. We await his next follow-up appointment to assess response. This case highlights the complexity of treating an immunocompromised individual with immunosuppressive agents, when the cause of their immunosuppression is unknown."

Journal • Atopic Dermatitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Herpes Zoster • Immunology • Infectious Disease • Mycosis Fungoides • Oncology • Solid Tumor • Thymoma • Thymus Cancer • Varicella Zoster • BTK • GATA2 • IL13

P106 Real-world experience of the efficacy and safety of tralokinumab use in atopic dermatitis: a multicentre audit. (PubMed, Br J Dermatol) - "Minor infections or viral illnesses were likely under-reported at follow-up, although there were no serious infections. Longer-term follow-up will provide further evidence of efficacy and safety outside of trial settings."

Journal • Real-world evidence • Retrospective data • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Dry Eye Disease • Immunology • Infectious Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • IL13

P012 Metastatic Staphylococcus aureus bacteraemia in atopic dermatitis: a case series. (PubMed, Br J Dermatol) - "IV, intravenousPatientClinical manifestationsComplications of SABTreatment of metastatic SABOutcome1Diaphoresis, rigors, nausea, fatigueMitral/aortic valve IE8 weeks IV flucloxacillinRecommenced on methotrexate; good control of AD2ErythrodermaMitral valve IE6 weeks IV flucloxacillinCommenced on dupilumab; excellent control of AD3Pyrexia and rigors following abscess development at footMitral/aortic valve IE6 weeks IV cefazolinMitral valve repair for mitral regurgitation. Recent commencement of dupilumab; AD improving4Erythroderma, subjective fevers, fatigueMRSA bacteraemia with mitral valve IETotal duration 6 weeks 6 days: IV vancomycin → IV daptomycin → IV ceftaroline + vancomycin → oral linezolidRecent recommencement of tralokinumab; AD improving5Right shoulder painSeptic arthritis of right shoulderIV flucloxacillin + vancomycin → 8 weeks daptomycin + rifampicin → 6 weeks doxycyclineCommenced on dupilumab; excellent control of ADAD, atopic dermatitis; IE, infective..."

Journal • Atopic Dermatitis • Cardiovascular • Cognitive Disorders • Dermatitis • Dermatology • Dermatopathology • Immunology • Infectious Disease • Inflammation • Musculoskeletal Pain • Pain • Rheumatology

Preclinical development of an anti-IL-13 antibody for the treatment of atopic dermatitis (ISDS 2025) - "Type 2 inflammatory pathway antagonism is safe and effective in the treatment of atopic dermatitis, with multiple approved drugs targeting the cytokine IL-13 (Ebglyss, Adbry) or its receptor IL-4R (Dupixent), and other IL-13 antagonists showing success in clinical development with half-life extended molecules (APG777). These molecules demonstrate pM IL-13 affinity, efficient antagonism of IL-13 signaling in both reporter cell lines and primary keratinocytes, extended half-life properties, and manufacturability and stability profiles consistent with commercially validated therapeutics. These candidates open the door to synergistic combinations pairing IL-13 antagonism with complementary pathway inhibition, for the treatment of inflammatory diseases like atopic dermatitis, particularly addressing patients whose disease remains inadequately controlled by existing systemic therapies."

Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • IL13 • IL4R